Sammy was partially correct. It was announced on 7/23 and released on 8/6, both crashing the share price.
What are you talking about? The competitors' respiratory virus panels give faster time to results and their enteric panels cover more infectious agents, including parasite pathogens and more viruses, than NSPH's. More pathogens means more accurate.
What are you talking about? Their products are not unique or esoteric. Others also have respiratory pathogen panels, enteric panels, and even have sepsis tests
1. An inflated self appraisal of his abilities. CHECK
2. Feelings of persecution. CHECK
3. Paranoia. CHECK
4. Blames others for his poor investment. CHECK
5. Obsessive compulsive ranting. CHECK
6. Delusions about other posters. CHECK
All of these are symptoms of someone that needs some serious professional therapy.
Management already downgrade guidance on 2014 instrument placements back in August.
You seem to be misinformed about everything you post here.
It is more likely that a fourth option will be the one that occurs in response to you having contacted them....nothing...business as usual.
The FDA has stated that there are 4 additional companies besides BioFire that have Ebola tests seeking Emergency Use Authorization.
NSPH is not one of them.
Over the weekend the FDA issued two Emergency Use Authorizations for BioFire's two Ebola tests. These rapid PCR-based tests may now be used by CLIA moderate complexity labs.
I assume you meant "dilution". The irrational pumpers here have more than enough delusion to go around.
Placements just aren't generating the revenue.
I understood correctly and noted the important facts and discounted the smoke and mirrors explanation from their last CC.
" U.S. customer placement base over 260 microbiology labs over half of which are producing consumable revenue."
So they are only generating revenue from slightly more than half of their "placements", meaning most are simply installs for evaluation purposes only. Evals provide the reagents and disposables at no cost.
You do know that you made a legally actionable libelous comment about tweeter, right?
I can see why people report you to a yahoo.
He is right about the Verigene Enteric Pathogens panel NOT detecting Ebola. This is copied and pasted directly from the FDA clearance documents and the NSPH website:
"For in vitro Diagnostic Use
TARGETS US/FDA Cleared Outside US
Campylobacter Group X X
Salmonella spp. X X
Shigella spp. X X
Vibrio Group X X
Yersinia enterocolitica X X
Shiga Toxin 1 (stx1) X X
Shiga Toxin 2 (stx2) X X
Norovirus X X
Rotavirus X X"
Ebola IS NOT part of the Verigene test and NSPH has NO Ebola test.
I suggest to check out NSPH's own website before you post more nonsense.
Sentiment: Strong Sell
NSPH DOES not HAVE an Ebola test. In fact, I invite you to check their website where Ebola is not mentioned ANYWHERE.
Sentiment: Strong Sell
Two days after you claimed you were done here and would no longer post here, yet you are still here spamming your derogatory bile.
Please get some help.
You seem unable to tell the truth. C. difficile is a bacteria that not only causes GI problems but that can also kill. And both their Strep and Strep B tests are for bacteria too.
The two companies ARE competitors, not complimentary.
When you stated that QDEL only had a viral pathogens test, not bacterial, you clearly showed you don't know what you are talking about.
QDEL already markets molecular tests for the following:
Group B Strep
As you can see, their tests cover BACTERIAL and viral disease, including some enteric/gastric as well as multiple respiratory viruses (not just flu) and sexually transmitted disases.
Please stop posting nonsense here.
You already disproved your hypothesis since QDEL has a competitor test(s) to NSPH's and has no need for their technology since it already has its own established molecular diagnostics program.
Damned you! You just made me laugh so hard while trying to sip hot coffee that I spewed it out of my nose all over my desk and almost choked!